Purinergic Signaling Pathway in Severe COVID-19

Overview

Journal Curr Opin Pharmacol

Specialty Pharmacology

Date 2023 Apr 23

PMID 37087844

Authors

Lourdes Arruvito

Ines Sananez

Vanesa Seery

Constanza Russo

Jorge Geffner

Affiliations

Soon will be listed here.

Abstract

Substantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation is usually associated to the release of ATP from different cell types, starting a cascade of events through the activation of a set of different purinergic receptors. This review summarizes the evidence showing the involvement of the purinergic system in the inflammatory condition that characterizes severe COVID-19.

Citing Articles

Melatonin from Plants: Going Beyond Traditional Central Nervous System Targeting-A Comprehensive Review of Its Unusual Health Benefits.

Fornari Laurindo L, Simili O, Cressoni Araujo A, Landgraf Guiguer E, Direito R, Valenti V Biology (Basel). 2025; 14(2).

PMID: 40001911 PMC: 11851571. DOI: 10.3390/biology14020143.

Melatonin's Impact on Cytokine Storm and Modulation of Purinergic Receptors for COVID-19 Prognosis: A Mental Health Perspective.

Bertollo A, Dalazen J, Cassol J, Hellmann M, Mota T, Ignacio Z J Mol Neurosci. 2024; 74(4):113.

PMID: 39636363 DOI: 10.1007/s12031-024-02292-6.

References

Dogan H, Senol O, Bolat S, Yildiz S, Buyuktuna S, Sariismailoglu R . Understanding the pathophysiological changes via untargeted metabolomics in COVID-19 patients. J Med Virol. 2020; 93(4):2340-2349. DOI: 10.1002/jmv.26716. View

Omarjee L, Meilhac O, Perrot F, Janin A, Mahe G . Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?. Clin Immunol. 2020; 216:108468. PMC: 7240255. DOI: 10.1016/j.clim.2020.108468. View

da Silva G, Manica D, da Silva A, Kosvoski G, Hanauer M, Assmann C . High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity. J Mol Med (Berl). 2022; 100(4):645-663. PMC: 8898096. DOI: 10.1007/s00109-022-02185-4. View

Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A . ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 2006; 314(5806):1792-5. DOI: 10.1126/science.1132559. View

Chen Y, Shao S, Hsu C, Wu I, Hung M, Chen Y . Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis. Crit Care. 2020; 24(1):346. PMC: 7296284. DOI: 10.1186/s13054-020-03009-y. View

Wang N, Vuerich M, Kalbasi A, Graham J, Csizmadia E, Manickas-Hill Z . Limited TCR repertoire and dysregulation mark late-stage COVID-19. iScience. 2021; 24(10):103205. PMC: 8482538. DOI: 10.1016/j.isci.2021.103205. View

Ribeiro D, Oliveira-Giacomelli A, Glaser T, Arnaud-Sampaio V, Andrejew R, Dieckmann L . Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology. Mol Psychiatry. 2020; 26(4):1044-1059. PMC: 7738776. DOI: 10.1038/s41380-020-00965-3. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Mao B, Guo W, Tang X, Zhang Q, Yang B, Zhao J . Inosine Pretreatment Attenuates LPS-Induced Lung Injury through Regulating the TLR4/MyD88/NF-κB Signaling Pathway In Vivo. Nutrients. 2022; 14(14). PMC: 9318366. DOI: 10.3390/nu14142830. View

10.

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

11.

Garcia-Villalba J, Hurtado-Navarro L, Penin-Franch A, Molina-Lopez C, Martinez-Alarcon L, Angosto-Bazarra D . Soluble P2X7 Receptor Is Elevated in the Plasma of COVID-19 Patients and Correlates With Disease Severity. Front Immunol. 2022; 13:894470. PMC: 9161710. DOI: 10.3389/fimmu.2022.894470. View

12.

Eckle T, Kewley E, Brodsky K, Tak E, Bonney S, Gobel M . Identification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury. J Immunol. 2014; 192(3):1249-56. PMC: 3946986. DOI: 10.4049/jimmunol.1100593. View

13.

Chekeni F, Elliott M, Sandilos J, Walk S, Kinchen J, Lazarowski E . Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature. 2010; 467(7317):863-7. PMC: 3006164. DOI: 10.1038/nature09413. View

14.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

15.

Junger W . Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011; 11(3):201-12. PMC: 4209705. DOI: 10.1038/nri2938. View

16.

Ludvigsson J . Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020; 109(6):1088-1095. PMC: 7228328. DOI: 10.1111/apa.15270. View

17.

Kim S, Kunapuli S . P2Y12 receptor in platelet activation. Platelets. 2011; 22(1):56-60. DOI: 10.3109/09537104.2010.497231. View

18.

Diaz-Garcia E, Garcia-Tovar S, Alfaro E, Zamarron E, Mangas A, Galera R . Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation. Front Immunol. 2022; 13:847894. PMC: 8841513. DOI: 10.3389/fimmu.2022.847894. View

19.

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J . Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020; 26(6):842-844. DOI: 10.1038/s41591-020-0901-9. View

20.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View